No arguments for extra risk from ibuprofen in SARS-COV2 infection

Therapie. Sep-Oct 2020;75(5):513-514. doi: 10.1016/j.therap.2020.07.006. Epub 2020 Jul 11.
[Article in French]
No abstract available

Keywords: COVID-19; Ibuprofen; SARS-CoV2.

Publication types

  • Letter

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • COVID-19 / drug therapy*
  • COVID-19 / epidemiology
  • COVID-19 / pathology
  • Chronic Disease
  • Confounding Factors, Epidemiologic
  • Disease Progression
  • Fever / complications
  • Fever / drug therapy
  • Fever / epidemiology
  • France / epidemiology
  • Humans
  • Ibuprofen / administration & dosage
  • Ibuprofen / adverse effects*
  • Pain / complications
  • Pain / drug therapy
  • Pain / epidemiology
  • Pandemics
  • Practice Guidelines as Topic / standards
  • Rheumatic Diseases / drug therapy
  • Rheumatic Diseases / epidemiology
  • Risk Factors
  • SARS-CoV-2 / physiology
  • Severity of Illness Index

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Ibuprofen